Market Research Logo

Oxytocic Pharmaceuticals Market: Labour Induction Segment Expected to Register Moderate Y-o-Y Growth Throughout the Forecast Period: Global Industry Analysis & Opportunity Assessment, 2016 - 2026

Oxytocic Pharmaceuticals Market: Labour Induction Segment Expected to Register Moderate Y-o-Y Growth Throughout the Forecast Period: Global Industry Analysis & Opportunity Assessment, 2016 - 2026

With a CAGR of 10.1%, the post-partum haemorrhage segment anticipated to lead the global oxytocic pharmaceuticals market in the coming decade

The post-partum haemorrhage segment was estimated to account for more than 75% market share of the global oxytocic pharmaceuticals market by the end of 2016 and is expected to gain more than 200 BPS in its market share by 2026. The post-partum haemorrhage segment is expected to register high Y-o-Y growth during the forecast period and is projected to remain the dominant segment during the forecast period. The post-partum haemorrhage segment is estimated to create absolute $ opportunity of more than US$ 5 Mn in 2017 over 2016. This segment dominated the global oxytocic pharmaceuticals market in terms of revenue in 2015, and the trend is projected to continue throughout the period of forecast.

Labour induction during childbirth is likely to boost the post-partum haemorrhage segment

Increasing childbirth using labour induction proves to be driving factor for the post-partum haemorrhage condition. There are certain situations – for instance, pre-eclampsia – where continuing the pregnancy is dangerous to the mother, or there are instances where women are uncomfortable, sore and tired. In such cases, labour is induced for convenience rather than medical reasons. However, labour induction increases the chances of post-partum haemorrhage. According to the World Health Organization, the rate of labour induction in developing countries is lower; but in developed countries, the rates are relatively high, which is creating a positive impact on the post-partum haemorrhage segment. Another factor which is likely to fuel the revenue growth of the post-partum haemorrhage segment is the increasing age of mothers. Older and heavier women and women who are smokers are more likely to bleed heavily after delivery. The ratio of getting pregnant after a certain age in life has increased in almost all the regions across the globe and this is creating robust development in the global oxytocic pharmaceuticals market, and specifically in the post-partum haemorrhage segment. Africa’s contribution to the prevalence of post-partum haemorrhage is likely to increase due to lack of healthcare infrastructure and awareness regarding pregnancy

The post-partum haemorrhage segment is the most attractive segment by indication in the North America oxytocic pharmaceuticals market, with a market attractiveness index of 3.9 estimated during the forecast period. In the Latin America region, the post-partum haemorrhage segment is estimated to reach a market attractiveness index of 3.7 due to increasing adolescent pregnancies. A majority of these pregnancies occur in Brazil in Latin America. An increase in labour induction procedures in the region is responsible for positioning post-partum haemorrhage as the most attractive indication segment. The MEA region represents a higher prevalence of post-partum haemorrhage among all the regions owing to lack of proper nutrition to pregnant women. Africa’s contribution to the prevalence of post-partum haemorrhage in the MEA region is on the higher end, owing to a lack of healthcare infrastructure and awareness regarding pregnancy related aspects among African women. Prevalence of post-partum haemorrhage is as high as 25.7% in African countries and 8.5% in Asian countries. In China, the post-partum haemorrhage segment is anticipated to record a market attractiveness index of 3.8 during the forecast period. A large pool of population and China’s altered single child policy to two children policy may likely increase the incidence of post-partum haemorrhage.

Opportunities in the global oxytocic pharmaceuticals market owing to rising instances of post-partum haemorrhage

Companies functioning in the global oxytocic pharmaceuticals market can reap larger market revenue from untapped markets in Asia and Africa where the prevalence of post-partum haemorrhage is on the higher side in comparison with other regions. Imparting awareness pertaining to pregnancy among the women in these regions can help create more market opportunities for existing as well as new entrants in the global oxytocic pharmaceuticals market.


1. Executive Summary
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
3. Global Oxytocic Pharmaceuticals Market Analysis Scenario
3.1. Market Size (US$ Mn) and Forecast
3.1.1. Market Size and Y-o-Y Growth
3.1.2. Absolute $ Opportunity
4. Market Dynamics
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
4.5. Number of procedures by Indications per region (2015-2026)
4.6. Number of procedures by End User per region (2015-2026)
4.7. Number of cervical ripening procedures by region (2015)
4.8. Comparative drugs list other than Oxytocin
5. Global Oxytocic Pharmaceuticals Market Analysis and Forecasts, By Indication
5.1. Introduction
5.2. Basis Point Share (BPS) Analysis By Indication Type
5.3. Y-o-Y Growth Projections By Indication Type
5.4. Market Value Forecast By Indication, 2016–2026
5.4.1. Abortion Induced Incomplete
5.4.2. Inevitable Abortion
5.4.3. Postpartum Hemorrhage
5.4.4. Labor Induction
5.4.5. Labor Arrest
5.5. Market Attractiveness By Indication
6. Global Oxytocic Pharmaceuticals Market Analysis and Forecasts, By End User
6.1. Introduction
6.2. Basis Point Share (BPS) Analysis By End User
6.3. Y-o-Y Growth Projections By End User
6.4. Market Value Forecast By End User, 2016–2026
6.4.1. Hospitals
6.4.2. Maternity Clinics
6.5. Market Attractiveness By End User
7. Global Oxytocic Pharmaceuticals Market Analysis and Forecasts, By Route of Administration
7.1. Introduction
7.2. Basis Point Share (BPS) Analysis By Route of Administration
7.3. Y-o-Y Growth Projections By Route of Administration
7.4. Market Value Forecast By Route of Administration, 2016–2026
7.4.1. Intravenous Infusion/Injection
7.4.2. Intramuscular Injection
7.5. Market Attractiveness By Route of Administration
8. Global Oxytocic Pharmaceuticals Market Analysis and Forecasts, By Source of Origin
8.1. Introduction
8.2. Basis Point Share (BPS) Analysis By Source of Origin
8.3. Y-o-Y Growth Projections By Source of Origin
8.4. Market Value Forecast By Source of Origin, 2016–2026
8.4.1. Synthetic Oxytocin Derivative
8.4.2. Natural Oxytocin (Animal Pituitary Extract)
8.5. Market Attractiveness By Source of Origin
9. Global Oxytocic Pharmaceuticals Market Analysis and Forecasts, By Region
9.1. Basis Point Share (BPS) Analysis By Region
9.2. Y-o-Y Growth Projections By Region
9.3. Market Value Forecast By Region
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. China
9.3.6. Japan
9.3.7. APEJC
9.3.8. MEA
9.4. Market Attractiveness By Region
10. North America Oxytocic Pharmaceuticals Market Analysis and Forecast
10.1.Introduction
10.1.1. Basis Point Share (BPS) Analysis By Country
10.1.2. Y-o-Y Growth Projections By Country
10.2.Market Value Forecast By Indication, 2016–2026
10.2.1. Abortion Induced Incomplete
10.2.2. Inevitable Abortion
10.2.3. Postpartum Hemorrhage
10.2.4. Labor Induction
10.2.5. Labor Arrest
10.3.Market Value Forecast By End User, 2016–2026
10.3.1. Hospitals
10.3.2. Maternity Clinics
10.4.Market Value Forecast By Route of Administration, 2016–2026
10.4.1. Intravenous Infusion/Injection
10.4.2. Intramuscular Injection
10.5.Market Value Forecast By Source of Origin, 2016–2026
10.5.1. Synthetic Oxytocin Derivative
10.5.2. Natural Oxytocin (Animal Pituitary Extract)
10.6.Market Value Forecast By Country, 2016–2026
10.6.1. US
10.6.2. Canada
10.7.Market Attractiveness Analysis
10.7.1. By Indication
10.7.2. By End User
10.7.3. By Route of Administration
10.7.4. By Source of Origin
10.7.5. By Country
10.8. Prominent Trends
11. Latin America Oxytocic Pharmaceuticals Market Analysis and Forecast
11.1.Introduction
11.1.1. Basis Point Share (BPS) Analysis By Country
11.1.2. Y-o-Y Growth Projections By Country
11.2.Market Value Forecast By Indication, 2016–2026
11.2.1. Abortion Induced Incomplete
11.2.2. Inevitable Abortion
11.2.3. Postpartum Hemorrhage
11.2.4. Labor Induction
11.2.5. Labor Arrest
11.3.Market Value Forecast By End User, 2016–2026
11.3.1. Hospitals
11.3.2. Maternity Clinics
11.4.Market Value Forecast By Route of Administration, 2016–2026
11.4.1. Intravenous Infusion/Injection
11.4.2. Intramuscular Injection
11.5.Market Value Forecast By Source of Origin, 2016–2026
11.5.1. Synthetic Oxytocin Derivative
11.5.2. Natural Oxytocin (Animal Pituitary Extract)
11.6.Market Value Forecast By Country, 2016–2026
11.6.1. Brazil
11.6.2. Mexico
11.6.3. Rest of Latin America
11.7.Market Attractiveness Analysis
11.7.1. By Indication
11.7.2. By End User
11.7.3. By Route of Administration
11.7.4. By Source of Origin
11.7.5. By Country
11.8. Prominent Trends
12. Western Europe Oxytocic Pharmaceuticals Market Analysis and Forecast
12.1.Introduction
12.1.1. Basis Point Share (BPS) Analysis By Country
12.1.2. Y-o-Y Growth Projections By Country
12.2.Market Value Forecast By Indication, 2016–2026
12.2.1. Abortion Induced Incomplete
12.2.2. Inevitable Abortion
12.2.3. Postpartum Hemorrhage
12.2.4. Labor Induction
12.2.5. Labor Arrest
12.3.Market Value Forecast By End User, 2016–2026
12.3.1. Hospitals
12.3.2. Maternity Clinics
12.4.Market Value Forecast By Route of Administration, 2016–2026
12.4.1. Intravenous Infusion/Injection
12.4.2. Intramuscular Injection
12.5.Market Value Forecast By Source of Origin, 2016–2026
12.5.1. Synthetic Oxytocin Derivative
12.5.2. Natural Oxytocin (Animal Pituitary Extract)
12.6.Market Value Forecast By Country, 2016–2026
12.6.1. UK
12.6.2. France
12.6.3. Germany
12.6.4. Italy
12.6.5. Spain
12.6.6. Benelux
12.6.7. Rest of Western Europe
12.7.Market Attractiveness Analysis
12.7.1. By Indication
12.7.2. By End User
12.7.3. By Route of Administration
12.7.4. By Source of Origin
12.7.5. By Country
12.8. Prominent Trends
13. Eastern Europe Oxytocic Pharmaceuticals Market Analysis and Forecast
13.1.Introduction
13.1.1. Basis Point Share (BPS) Analysis By Country
13.1.2. Y-o-Y Growth Projections By Country
13.2.Market Value Forecast By Indication, 2016–2026
13.2.1. Abortion Induced Incomplete
13.2.2. Inevitable Abortion
13.2.3. Postpartum Hemorrhage
13.2.4. Labor Induction
13.2.5. Labor Arrest
13.3.Market Value Forecast By End User, 2016–2026
13.3.1. Hospitals
13.3.2. Maternity Clinics
13.4.Market Value Forecast By Route of Administration, 2016–2026
13.4.1. Intravenous Infusion/Injection
13.4.2. Intramuscular Injection
13.5.Market Value Forecast By Source of Origin, 2016–2026
13.5.1. Synthetic Oxytocin Derivative
13.5.2. Natural Oxytocin (Animal Pituitary Extract)
13.6.Market Value Forecast By Country, 2016–2026
13.6.1. Russia
13.6.2. Poland
13.6.3. Rest of Eastern Europe
13.7.Market Attractiveness Analysis
13.7.1. By Indication
13.7.2. By End User
13.7.3. By Route of Administration
13.7.4. By Source of Origin
13.7.5. By Country
13.8. Prominent Trends
14. APEJC Oxytocic Pharmaceuticals Market Analysis and Forecast
14.1.Introduction
14.1.1. Basis Point Share (BPS) Analysis By Country
14.1.2. Y-o-Y Growth Projections By Country
14.2.Market Value Forecast By Indication, 2016–2026
14.2.1. Abortion Induced Incomplete
14.2.2. Inevitable Abortion
14.2.3. Postpartum Hemorrhage
14.2.4. Labor Induction
14.2.5. Labor Arrest
14.3.Market Value Forecast By End User, 2016–2026
14.3.1. Hospitals
14.3.2. Maternity Clinics
14.4.Market Value Forecast By Route of Administration, 2016–2026
14.4.1. Intravenous Infusion/Injection
14.4.2. Intramuscular Injection
14.5.Market Value Forecast By Source of Origin, 2016–2026
14.5.1. Synthetic Oxytocin Derivative
14.5.2. Natural Oxytocin (Animal Pituitary Extract)
14.6.Market Value Forecast By Country, 2016–2026
14.6.1. India
14.6.2. Australia & New Zealand
14.6.3. ASEAN
14.6.4. Rest of APEJC
14.7.Market Attractiveness Analysis
14.7.1. By Indication
14.7.2. By End User
14.7.3. By Route of Administration
14.7.4. By Source of Origin
14.7.5. By Country
14.8. Prominent Trends
15. Japan Oxytocic Pharmaceuticals Market Analysis and Forecast
15.1.Introduction
15.1.1. Basis Point Share (BPS) Analysis By Country
15.1.2. Y-o-Y Growth Projections By Country
15.2.Market Value Forecast By Indication, 2016–2026
15.2.1. Abortion Induced Incomplete
15.2.2. Inevitable Abortion
15.2.3. Postpartum Hemorrhage
15.2.4. Labor Induction
15.2.5. Labor Arrest
15.3.Market Value Forecast By End User, 2016–2026
15.3.1. Hospitals
15.3.2. Maternity Clinics
15.4.Market Value Forecast By Route of Administration, 2016–2026
15.4.1. Intravenous Infusion/Injection
15.4.2. Intramuscular Injection
15.5.Market Value Forecast By Source of Origin, 2016–2026
15.5.1. Synthetic Oxytocin Derivative
15.5.2. Natural Oxytocin (Animal Pituitary Extract)
15.6.Market Attractiveness Analysis
15.6.1. By Indication
15.6.2. By End User
15.6.3. By Route of Administration
15.6.4. By Source of Origin
15.7. Prominent Trends
16. MEA Oxytocic Pharmaceuticals Market Analysis and Forecast
16.1.Introduction
16.1.1. Basis Point Share (BPS) Analysis By Country
16.1.2. Y-o-Y Growth Projections By Country
16.2.Market Value Forecast By Indication, 2016–2026
16.2.1. Abortion Induced Incomplete
16.2.2. Inevitable Abortion
16.2.3. Postpartum Hemorrhage
16.2.4. Labor Induction
16.2.5. Labor Arrest
16.3.Market Value Forecast By End User, 2016–2026
16.3.1. Hospitals
16.3.2. Maternity Clinics
16.4.Market Value Forecast By Route of Administration, 2016–2026
16.4.1. Intravenous Infusion/Injection
16.4.2. Intramuscular Injection
16.5.Market Value Forecast By Source of Origin, 2016–2026
16.5.1. Synthetic Oxytocin Derivative
16.5.2. Natural Oxytocin (Animal Pituitary Extract)
16.6.Market Value Forecast By Country, 2016–2026
16.6.1. GCC Countries
16.6.2. South Africa
16.6.3. Rest of MEA
16.7.Market Attractiveness Analysis
16.7.1. By Indication
16.7.2. By End User
16.7.3. By Route of Administration
16.7.4. By Source of Origin
16.7.5. By Country
16.8. Prominent Trends
17. China Oxytocic Pharmaceuticals Market Analysis and Forecast
17.1.Introduction
17.1.1. Basis Point Share (BPS) Analysis By Country
17.1.2. Y-o-Y Growth Projections By Country
17.2.Market Value Forecast By Indication, 2016–2026
17.2.1. Abortion Induced Incomplete
17.2.2. Inevitable Abortion
17.2.3. Postpartum Hemorrhage
17.2.4. Labor Induction
17.2.5. Labor Arrest
17.3.Market Value Forecast By End User, 2016–2026
17.3.1. Hospitals
17.3.2. Maternity Clinics
17.4.Market Value Forecast By Route of Administration, 2016–2026
17.4.1. Intravenous Infusion/Injection
17.4.2. Intramuscular Injection
17.5.Market Value Forecast By Source of Origin, 2016–2026
17.5.1. Synthetic Oxytocin Derivative
17.5.2. Natural Oxytocin (Animal Pituitary Extract)
17.6.Market Attractiveness Analysis
17.6.1. By Indication
17.6.2. By End User
17.6.3. By Route of Administration
17.6.4. By Source of Origin

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report